Abstract
Deferoxamine (DFO), an efficient chelating agent available for the treatment of iron and aluminium overload, was evaluated for developmental toxicity in Swiss mice. Intraperitoneal injections of DFO were given to pregnant animals at 0, 44, 88, 176, and 352 mg/kg per day on gestational days 6 through 15. Maternal clinical status was monitored daily during and after treatment. Fetal parameters, including external, visceral, and skeletal malformations and variations, were assessed. Mice were killed on day 18. No maternal mortality was observed, but dams exhibited reduced body weight gain during treatment at 88, 176, and 352 mg/kg per day. Body weight at termination, corrected body wieght, and food consumption were reduced in all groups. In contrast, the only significant treatment-related embryo/fetal effect was a decrease in the number of live fetuses per litter at 352 mg/kg per day. The no-observable-adverse-effect level (NOAEL) for maternal toxicity of DFO was < 44 mg/kg per day, whereas the NOAEL for developmental toxicity was 176 mg/kg per day. In summary, intraperitoneal administration of DFO to mice during organogenesis produced developmental toxicity in the presence of maternal toxicity. Because of the remarkable maternal toxicity of DFO, extreme caution in the use of this drug is recommended during pregnancy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Ackrill P, Day JP (1985) Desferrioxamine in the treatment of aluminium overload. Clin Nephrol 24: S94-S97
Barry M, Flynn DM, Letsky EA, Risdon RA (1974) Long-term chelation therapy in thalassemia major: effect of liver iron concentration, liver histology, and clinical progress. BMJ 2: 16–20
Black DL, Marks TA (1986) Inconsistent use of terminology in animal developmental toxicology studies: a discussion Teratology 33: 333–338
Blanc P, Hryhorczuk D, Danel I (1984) Deferoxamine treatment of acute iron intoxication in pregnancy Obstet Gynecol 64: 12S-14S
Boelaert JR, Van Cutsem J, De Locht M, Schneider YJ, Crichton RR (1994) Deteroxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int 45: 667–671
Cases A, Kelly J, Sabater F, Torras A, Griño MC, Lopez-Pedret J, Revert L (1990) Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine. Nephron 56: 19–23
Domingo JL (1989) The use of chelating agents in the treatment of aluminium overload. J Toxicol Clin Toxicol 27: 355–367
Domingo JL, Gomez M, Llobet J, Corbella JM (1990) Chelating agents in the treatment of acute vanadyl sulphate intoxication in mice. Toxicology 62: 203–211
Gallant T, Boyden MH, Carley H, Freedman MH (1987) Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy. An J Med 83: 1085–1090
Hoffbrand AV, Wonke B (1989) Results of long-term subcutaneous desferrioxamine therapy. Baillierie’s Clin Hematol 2: 345–362
Khera KS (1984) Maternal toxicity. A possible factor in fetal malformations in mice. Teratology 29: 411–416
Khera KS (1985) Maternal toxicity: a possible etiological factor in embryo-fetal deaths and fetal malformations of rodent-rabbit species. Teratology 31: 129–136
Lauro V, Giornelli C, Stantilli Giornelli FE, Fanelli A (1968) Effetti di un ferro-chelante sulla gravidanza della ratta. Indagini sperimentali. Arch Ostet Ginecol 73: 269–283
Malluche HH, Smith AJ, Abreo K, Faugere MC (1984) The use of desferrioxamine in the management of aluminium accumulation in bone in patients with renal failure. N Engl J Med 311: 140–144
Martin K (1983) Successful pregnancy in beta-thalassemia major. Aust Paediatr J 19: 182–183
McElhatton PR, Roberts JC, Sullivan FM (1991) The consequences of iron overdose and its treatment with desferrioxamine in pregnancy. Hum Exp Toxicol 10: 251–259
Molitoris BA, Alfrey AC, Alfrey PS, Miller NL (1988) Rapid removal of DFO-chelated aluminium during hemodialysis using polysulfone dialyzers. Kidney Int 34: 98–101
Olenmark M, Biber B, Dottori O, Rybo G (1987) Fatal iron intoxication in late pregnancy. J Toxicol Clin Toxicol 25: 347–359
Porter JB, Huehns ER (1989) The toxic effects of desferrioxamine. Bailliere’s Clin Hematol 2: 459–474
Sephton-Smith R (1962) Iron excretion in thalassemia major after administration of chelating agents. BMJ 2: 1577–1580
Staples RE, Schnell VL (1968) Refinements in rapid clearing technique in the KOH-alizarin red S method for fetal bone. Stain Technol 43: 61–63
Swartz RD (1985) Deferoxamine and aluminium removal. Am J Kidney Dis 6: 358–364
Tenenbein M (1990) Poisoning in pregnancy. In: Koren G (ed) Maternal-fetal toxicology: a clinical guide. Marcel Dekker, New York, pp 89–114
Tenenbein M, Kowalski S, Sienko A, Bowden DH, Adamson IYR (1992) Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. Lancet 339: 699–701
Thomas RM, Skalicka AE (1980) Successful pregnancy in transfusion-dependent thalassemia. Arch Dis Child 55: 572–574
Tielmans C, Collart F, Wens R, Smeyers-Verbeeke J, Van Hoof I, Dratwa M, Verbeelen D (1985) Improvement of anemia with deferoxamine in hemodialysis patients with aluminium-induced bone disease. Clin Nephrol 24: 237–241
Wilson JG (1965) Embryological considerations in teratology. In: Wilson JG, Warkany J (eds) Teratology: principles and techniques. University of Chicago Press, Chicago, pp 251–277
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bosque, M.A., Domingo, J.L. & Corbella, J. Assessment of the developmental toxicity of deferoxamine in mice. Arch Toxicol 69, 467–471 (1995). https://doi.org/10.1007/s002040050200
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s002040050200